Study of extended Letrozole treatment protocol (7 and 10 days) on the ovulation induction and clinical pregnancy in conventional treatment-resistant (5 days) Poly Cystic Ovary Syndrome patients

Esfahan University of Medical Sciences0 个研究点目标入组 66 人开始时间: 待定最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•BMI less than 35
•PCOS diagnosis based on Rotterdam criteria
•Male sexual health(A sperm concentration of 14 million per milliliter, with the presence of motile sperm observed in at least one ejaculation within the past year.)
•willingness to engage in regular sexual intercourse during the period of the study
•Consent to participate in the study (this consent includes both partners, as the informed cooperation and participation of the wife is also one of the necessities of the study
•No response to the treatment with 5 milligrams of Letrozole for 5 days

•Patients who have uncontrolled thyroid disease or hyperprolactinemia, or a testosterone level exceeding 150 nanograms per milliliter.
•Contraindication for pregnancy
•Concurrent administration of other ovulation inducers such as Metformin, Clomiphene Citrate, and Gonadotropins
•Unwillingness to enter to the study
•Use of drugs that interact with Letrozole
•Previous hypersensitivity to the Letrozole
•Positive pregnancy test
•Use of fertility-affecting drugs in the past three months, including: OCP, GnRH agonists and antagonists, anti-androgens, gonadotropins, antiobesity drugs, somatostatin, diazoxide, ACE inhibitors, and calcium channel blockers. No past anti-fertility activities such as vasectomy and fallopian tube ligation.
•Patients with very high androgen levels are initially screened for Cushing’s syndrome (urinary cortisol level) and adult adrenal hyperplasia (by measuring 17-a-hydroxyl-progesterone). If these conditions are present, they are not included in the study

发起方